DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.36

Change

-0.06 (-0.71)%

Market Cap

USD 0.17B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.42 (+0.41%)

USD 16.82B
IVV:AU iShares Core S&P 500 AUD

+0.72 (+1.18%)

USD 8.73B
VGS:AU Vanguard MSCI International Sh..

+1.31 (+0.97%)

USD 8.59B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.52 (+0.91%)

USD 6.70B
IOZ:AU Ishares Core S&P/Asx 200

+0.15 (+0.45%)

USD 6.18B
STW:AU SPDR® S&P/ASX 200 Fund

+0.35 (+0.47%)

USD 5.58B
NDQ:AU Betashares Nasdaq 100

+0.51 (+1.07%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.01 (-0.02%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.65 (+0.47%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+4.82 (+1.06%)

USD 4.71B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.56% 37% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.56% 38% F 51% F
Trailing 12 Months  
Capital Gain 11.02% 40% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.02% 40% F 51% F
Trailing 5 Years  
Capital Gain 34.19% 75% C 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.19% 75% C 58% F
Average Annual (5 Year Horizon)  
Capital Gain 7.03% 76% C+ 56% F
Dividend Return 8.58% 72% C 54% F
Total Return 1.56% 52% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 8.43% 64% D 93% A
Risk Adjusted Return 101.89% 95% A 98% N/A
Market Capitalization 0.17B 34% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.